Santen Pharmaceutical Co., Ltd.

DB:SZD Stock Report

Market Cap: €3.2b

Santen Pharmaceutical Valuation

Is SZD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SZD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SZD (€9.4) is trading below our estimate of fair value (€20.53)

Significantly Below Fair Value: SZD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SZD?

Key metric: As SZD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SZD. This is calculated by dividing SZD's market cap by their current earnings.
What is SZD's PE Ratio?
PE Ratio20.3x
EarningsJP¥26.12b
Market CapJP¥530.71b

Price to Earnings Ratio vs Peers

How does SZD's PE Ratio compare to its peers?

The above table shows the PE ratio for SZD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
DMP Dermapharm Holding
22.6x17.0%€2.0b
PSG PharmaSGP Holding
16.1x13.6%€302.2m
MRK Merck KGaA
22.3x11.1%€60.2b
2FJ0 Pierrel
29.9xn/a€92.8m
SZD Santen Pharmaceutical
20.3x11.5%€530.7b

Price-To-Earnings vs Peers: SZD is good value based on its Price-To-Earnings Ratio (20.3x) compared to the peer average (22.7x).

Price to Earnings Ratio vs Industry

How does SZD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SZD 20.3xIndustry Avg. 19.5xNo. of Companies12PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SZD is expensive based on its Price-To-Earnings Ratio (20.3x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is SZD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SZD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.3x
Fair PE Ratio16.1x

Price-To-Earnings vs Fair Ratio: SZD is expensive based on its Price-To-Earnings Ratio (20.3x) compared to the estimated Fair Price-To-Earnings Ratio (16.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SZD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.40
€13.25
+40.9%
14.5%€16.42€10.73n/a10
Dec ’25€10.60
€13.12
+23.8%
14.5%€16.27€10.63n/a10
Nov ’25€10.60
€12.97
+22.4%
15.2%€15.69€9.72n/a10
Oct ’25€10.80
€12.97
+20.1%
15.2%€15.69€9.72n/a10
Sep ’25€11.40
€12.22
+7.2%
15.2%€15.40€9.55n/a10
Aug ’25€10.80
€12.07
+11.8%
14.8%€14.80€9.86n/a10
Jul ’25€9.45
€11.09
+17.3%
18.6%€14.26€7.72n/a9
Jun ’25€9.45
€10.73
+13.5%
19.2%€14.10€7.64n/a10
May ’25€9.00
€10.79
+19.8%
15.8%€13.43€7.94n/a10
Apr ’25€9.00
€10.79
+19.8%
15.8%€13.43€7.94n/a10
Mar ’25€9.05
€10.69
+18.1%
16.2%€13.52€7.99n/a9
Feb ’25€9.20
€10.46
+13.7%
16.3%€13.12€8.12n/a9
Jan ’25€8.90
€10.41
+17.0%
16.0%€12.73€7.64n/a9
Dec ’24€8.80
€9.97
+13.3%
16.7%€12.28€7.37€10.609
Nov ’24€8.05
€9.94
+23.4%
14.5%€11.91€7.52€10.609
Oct ’24€8.45
€9.70
+14.8%
16.3%€11.71€7.60€10.807
Sep ’24€8.35
€8.87
+6.3%
20.1%€11.70€6.32€11.409
Aug ’24€7.75
€8.72
+12.5%
19.1%€11.50€6.39€10.809
Jul ’24€7.55
€8.49
+12.5%
20.8%€11.43€6.35€9.459
Jun ’24€8.30
€8.96
+7.9%
21.7%€11.94€6.50€9.4510
May ’24€7.45
€8.63
+15.9%
20.5%€11.99€6.53€9.0010
Apr ’24€7.60
€8.95
+17.8%
24.3%€13.53€6.04€9.0010
Mar ’24€6.85
€9.07
+32.5%
24.4%€13.66€6.10€9.0510
Feb ’24€7.30
€8.99
+23.2%
26.0%€13.86€6.18€9.2010
Jan ’24€7.40
€8.82
+19.2%
25.9%€13.59€6.13€8.9010
Dec ’23€7.50
€8.69
+15.9%
26.4%€13.61€6.14€8.8010

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 02:41
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Philip HallBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research